CYP19A1 and breast carcinoma: Aromatase inhibitors (AIs), such as anastrozole, constitute an important approach for reducing growth-stimulatory effects of estrogens in estrogen-dependent ER and PR-positive postmenopausal breast cancer patients [7,8].